Mycobacterium Xenopi Pulmonary Infection clinical trials

Explore recruiting mycobacterium xenopi pulmonary infection clinical trials.

Recruiting mycobacterium xenopi pulmonary infection studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mycobacterium Xenopi Pulmonary Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-label randomized study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Mycobacterium Xenopi Pulmonary Infection trials by city

Mycobacterium Xenopi Pulmonary Infection in Toronto Mycobacterium Xenopi Pulmonary Infection in Vancouver Mycobacterium Xenopi Pulmonary Infection in Montreal Mycobacterium Xenopi Pulmonary Infection in Calgary Mycobacterium Xenopi Pulmonary Infection in Edmonton Mycobacterium Xenopi Pulmonary Infection in Ottawa Mycobacterium Xenopi Pulmonary Infection in Winnipeg Mycobacterium Xenopi Pulmonary Infection in Quebec City Mycobacterium Xenopi Pulmonary Infection in Hamilton Mycobacterium Xenopi Pulmonary Infection in Kitchener Mycobacterium Xenopi Pulmonary Infection in London Mycobacterium Xenopi Pulmonary Infection in Halifax Mycobacterium Xenopi Pulmonary Infection in New York Mycobacterium Xenopi Pulmonary Infection in Los Angeles Mycobacterium Xenopi Pulmonary Infection in Chicago Mycobacterium Xenopi Pulmonary Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease